PharmChem, Inc. Announces Shareholder Approval of Acquisition by Alcohol Monitoring Systems, Inc.

FORT WORTH, Texas, Aug. 27, 2025 /PRNewswire/ -- PharmChem, Inc. ("PharmChem" or the "Company") (OTC: PCHM) is pleased to announce that its acquisition by Alcohol Monitoring Systems, Inc., was approved by shareholders at today's special meeting. Per the agreement, shareholders of PharmChem will receive $3.75 per share in cash upon final closing.

The Company expects the consummation of the transaction to be effective at the close of business on Thursday, August 28, 2025.

If shareholders have further, specific questions, please email our CFO Shana Veale at sveale@pharmchem.com and we will set up a call.

Tim Eriksen
Chairman of the Board

About PharmChem, Inc.

PharmChem, Inc. ("PharmChem") (OTC: PCHM), headquartered in Fort Worth, TX, is the manufacturer and sole source provider of the PharmChek® Drugs of Abuse Sweat Patch.

Safe Harbor for Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933 ("Forward-looking Statements"), which are subject to the "safe harbor" created by these Sections. Forward-looking statements are statements about future financial results, future products or services and www.pharmchem.com other events that have not yet occurred. These forward-looking statements contain words such as, but not limited to, "expect", "anticipate", "estimate", "believe", "will", "may" or "might". Investors should be aware that actual results may differ materially from our expressed expectations because of risks and uncertainties about the future. We will not necessarily update the information in this letter if any forward-looking statement later turns out to be inaccurate.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmchem-inc-announces-shareholder-approval-of-acquisition-by-alcohol-monitoring-systems-inc-302540192.html

SOURCE PharmChem, Inc.